立昂技術(300603.SZ):1560.0441萬股限售股將解禁
格隆匯1月26日丨立昂技術(300603.SZ)公佈,公司此次解除限售的股份為公司發行股份及支付現金購買資產之部分限售股份。
此次解除限售的股份數量為1560.0441萬股,佔公司總股本的4.22%;其中,實際可上市流通的數量為7,073,665股,佔公司總股本的1.91%。
此次解除限售股份可上市流通日為2022年2月7日。
此次解除限售後,相關股東在減持股份時將嚴格遵照《上市公司股東、董監高減持股份的若干規定》、《深圳證券交易所上市公司股東及董事、監事、高級管理人員減持股份實施細則》等相關法律法規的要求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.